From: Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
 | IR | IGF1R | IR/IGF1R | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Low | High | p value | Low | High | p value | < 1 | 1 | > 1 | p value | |
Number of cases (%) | 84 (43%) | 112 (57%) | Â | 68 (35%) | 128 (65%) | Â | 101 (52%) | 64 (33%) | 30 (15%) | Â |
Age (mean ± SD, years) | 58.7 ± 11.4 | 58.7 ± 12.9 | 0.985 | 58.9 ± 12.4 | 58.6 ± 12.2 | 0.862 | 58.1 ± 12.1 | 60.0 ± 11.3 | 57.5 ± 14.7 | 0.530 |
Race | Â | Â | 0.004 | Â | Â | 0.430 | Â | Â | Â | 0.003 |
 White | 77 (48%) | 85 (52%) |  | 54 (33%) | 108 (67%) |  | 89 (55%) | 54 (34%) | 18 (11%) |  |
 Black | 7 (21%) | 27 (79%) |  | 14 (41%) | 20 (59%) |  | 12 (35%) | 10 (29%) | 12 (35%) |  |
Metabolic characteristics | ||||||||||
 BMI (mean ± SD) | 26.6 ± 5.7 | 28.2 ± 6.9 | 0.091 | 28.0 ± 5.7 | 27.2 ± 6.9 | 0.461 | 26.5 ± 6.4 | 27.7 ± 6.7 | 30.0 ± 5.7 | 0.039 |
 Waist circumference (mean ± SD) | 93.1 ± 15.2 | 100.4 ± 14.7 | 0.002 | 96.1 ± 14.5 | 98.0 ± 15.8 | 0.438 | 95.6 ± 15.2 | 99.3 ± 15.6 | 100.3 ± 13.2 | 0.203 |
 HOMA-IR score, (mean ± SD) | 1.2 ± 1.1 | 1.3 ± 1.1 | 0.635 | 1.3 ± 1.1 | 1.3 ± 1.1 | 0.649 | 1.2 ± 1.1 | 1.3 ± 1.0 | 1.6 ± 1.3 | 0.321 |
Tumor characteristics | ||||||||||
 TNBC | 3 (27%) | 8 (73%) | 0.363 | 6 (55%) | 5 (45%) | 0.191 | 2 (18%) | 6 (55%) | 3 (27%) | 0.051 |
 ER positive | 69 (41%) | 99 (59%) | 0.391 | 49 (29%) | 119 (71%) | < .001 | 96 (57%) | 47 (28%) | 24 (14%) | < .001 |
 HER2 positive | 4 (33%) | 8 (67%) | 0.565 | 8 (67%) | 4 (33%) | 0.025 | 3 (25%) | 4 (33%) | 5 (42%) | 0.032 |
 NPI (mean ± SD) | 3.6 ± 0.8 | 3.8 ± 1.0 | 0.167 | 4.1 ± 0.8 | 3.6 ± 1.0 | < .001 | 3.5 ± 1.0 | 3.9 ± 0.8 | 4.2 ± 0.8 | < .001 |
 iNPI (mean ± SD) | 3.0 ± 1.1 | 3.2 ± 1.2 | 0.443 | 3.6 ± 1.1 | 2.9 ± 1.1 | < .001 | 2.8 ± 1.2 | 3.3 ± 1.1 | 3.8 ± 1.1 | < .001 |